Literature DB >> 27627691

Polyubiquitinylation Profile in Down Syndrome Brain Before and After the Development of Alzheimer Neuropathology.

Antonella Tramutola1, Fabio Di Domenico1, Eugenio Barone1, Andrea Arena1, Alessandra Giorgi1, Laura di Francesco1, Maria Eugenia Schininà1, Raffaella Coccia1, Elizabeth Head2,3, D Allan Butterfield2,4, Marzia Perluigi1.   

Abstract

AIMS: Among the putative mechanisms proposed to be common factors in Down syndrome (DS) and Alzheimer's disease (AD) neuropathology, deficits in protein quality control (PQC) have emerged as a unifying mechanism of neurodegeneration. Considering that disturbance of protein degradation systems is present in DS and that oxidized/misfolded proteins require polyubiquitinylation for degradation via the ubiquitin proteasome system, this study investigated if dysregulation of protein polyubiquitinylation is associated with AD neurodegeneration in DS.
RESULTS: Postmortem brains from DS cases before and after development of AD neuropathology and age-matched controls were analyzed. By selectively isolating polyubiquitinated proteins, we were able to identify specific proteins with an altered pattern of polyubiquitinylation as a function of age. Interestingly, we found that oxidation is coupled with polyubiquitinylation for most proteins mainly involved in PQC and energy metabolism. INNOVATION: This is the first study showing alteration of the polyubiquitinylation profile as a function of aging in DS brain compared with healthy controls. Understanding the onset of the altered ubiquitome profile in DS brain may contribute to identification of key molecular regulators of age-associated cognitive decline.
CONCLUSIONS: Disturbance of the polyubiquitinylation machinery may be a key feature of aging and neurodegeneration. In DS, age-associated deficits of the proteolytic system may further exacerbate the accumulation of oxidized/misfolded/polyubiquitinated proteins, which is not efficiently degraded and may become harmful to neurons and contribute to AD neuropathology. Antioxid. Redox Signal. 26, 280-298.

Entities:  

Keywords:  Alzheimer disease; Down syndrome; proteasome; proteomics; trisomy21; ubiquitin

Mesh:

Substances:

Year:  2016        PMID: 27627691      PMCID: PMC5327052          DOI: 10.1089/ars.2016.6686

Source DB:  PubMed          Journal:  Antioxid Redox Signal        ISSN: 1523-0864            Impact factor:   8.401


  75 in total

Review 1.  Protein degradation and protection against misfolded or damaged proteins.

Authors:  Alfred L Goldberg
Journal:  Nature       Date:  2003-12-18       Impact factor: 49.962

Review 2.  Protein degradation by the ubiquitin-proteasome pathway in normal and disease states.

Authors:  Stewart H Lecker; Alfred L Goldberg; William E Mitch
Journal:  J Am Soc Nephrol       Date:  2006-05-31       Impact factor: 10.121

Review 3.  Redox proteomics in selected neurodegenerative disorders: from its infancy to future applications.

Authors:  D Allan Butterfield; Marzia Perluigi; Tanea Reed; Tasneem Muharib; Christopher P Hughes; Renã A S Robinson; Rukhsana Sultana
Journal:  Antioxid Redox Signal       Date:  2012-01-18       Impact factor: 8.401

Review 4.  Beta-amyloid, oxidative stress and down syndrome.

Authors:  Ira T Lott; Elizabeth Head; Eric Doran; Jorge Busciglio
Journal:  Curr Alzheimer Res       Date:  2006-12       Impact factor: 3.498

5.  Proteomic identification of oxidatively modified proteins in Alzheimer's disease brain. Part I: creatine kinase BB, glutamine synthase, and ubiquitin carboxy-terminal hydrolase L-1.

Authors:  Alessandra Castegna; Michael Aksenov; Marina Aksenova; Visith Thongboonkerd; Jon B Klein; William M Pierce; Rosemarie Booze; William R Markesbery; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2002-08-15       Impact factor: 7.376

6.  The ubiquitin-proteasome system and the autophagic-lysosomal system in Alzheimer disease.

Authors:  Yasuo Ihara; Maho Morishima-Kawashima; Ralph Nixon
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

7.  Collapse of proteostasis represents an early molecular event in Caenorhabditis elegans aging.

Authors:  Anat Ben-Zvi; Elizabeth A Miller; Richard I Morimoto
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-24       Impact factor: 11.205

8.  Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips.

Authors:  Juri Rappsilber; Matthias Mann; Yasushi Ishihama
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

Review 9.  The functions of UCH-L1 and its relation to neurodegenerative diseases.

Authors:  Rieko Setsuie; Keiji Wada
Journal:  Neurochem Int       Date:  2007-05-24       Impact factor: 3.921

10.  Accelerated epigenetic aging in Down syndrome.

Authors:  Steve Horvath; Paolo Garagnani; Maria Giulia Bacalini; Chiara Pirazzini; Stefano Salvioli; Davide Gentilini; Anna Maria Di Blasio; Cristina Giuliani; Spencer Tung; Harry V Vinters; Claudio Franceschi
Journal:  Aging Cell       Date:  2015-02-09       Impact factor: 9.304

View more
  21 in total

1.  Polyubiquitin Profile in Down Syndrome and Alzheimer's Disease Brain.

Authors:  Antonella Tramutola; Marzia Perluigi
Journal:  Methods Mol Biol       Date:  2021

Review 2.  mTOR in Down syndrome: Role in Aß and tau neuropathology and transition to Alzheimer disease-like dementia.

Authors:  Fabio Di Domenico; Antonella Tramutola; Cesira Foppoli; Elizabeth Head; Marzia Perluigi; D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2017-08-12       Impact factor: 7.376

Review 3.  Disturbance of redox homeostasis in Down Syndrome: Role of iron dysmetabolism.

Authors:  Eugenio Barone; Andrea Arena; Elizabeth Head; D Allan Butterfield; Marzia Perluigi
Journal:  Free Radic Biol Med       Date:  2017-07-10       Impact factor: 7.376

4.  Early and Selective Activation and Subsequent Alterations to the Unfolded Protein Response in Down Syndrome Mouse Models.

Authors:  Chiara Lanzillotta; Antonella Tramutola; Shelby Meier; Frederick Schmitt; Eugenio Barone; Marzia Perluigi; Fabio Di Domenico; Jose F Abisambra
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

Review 5.  Ubiquitin carboxyl-terminal hydrolase L-1 in brain: Focus on its oxidative/nitrosative modification and role in brains of subjects with Alzheimer disease and mild cognitive impairment.

Authors:  D Allan Butterfield
Journal:  Free Radic Biol Med       Date:  2021-11-01       Impact factor: 7.376

6.  Meloxicam Inhibits Apoptosis in Neurons by Deactivating Tumor Necrosis Factor Receptor Superfamily Member 25, Leading to the Decreased Cleavage of DNA Fragmentation Factor Subunit α in Alzheimer's Disease.

Authors:  Peipei Guan; Di Zhu; Pu Wang
Journal:  Mol Neurobiol       Date:  2022-10-24       Impact factor: 5.682

Review 7.  Dysfunction of autophagy and endosomal-lysosomal pathways: Roles in pathogenesis of Down syndrome and Alzheimer's Disease.

Authors:  Daniel J Colacurcio; Anna Pensalfini; Ying Jiang; Ralph A Nixon
Journal:  Free Radic Biol Med       Date:  2017-10-06       Impact factor: 7.376

8.  Hemoglobin oxidation-dependent reactions promote interactions with band 3 and oxidative changes in sickle cell-derived microparticles.

Authors:  Sirsendu Jana; Michael Brad Strader; Fantao Meng; Wayne Hicks; Tigist Kassa; Ivan Tarandovskiy; Silvia De Paoli; Jan Simak; Michael R Heaven; John D Belcher; Gregory M Vercellotti; Abdu I Alayash
Journal:  JCI Insight       Date:  2018-11-02

9.  The Dysregulation of OGT/OGA Cycle Mediates Tau and APP Neuropathology in Down Syndrome.

Authors:  Ilaria Zuliani; Chiara Lanzillotta; Antonella Tramutola; Antonio Francioso; Sara Pagnotta; Eugenio Barone; Marzia Perluigi; Fabio Di Domenico
Journal:  Neurotherapeutics       Date:  2020-11-30       Impact factor: 7.620

Review 10.  Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease.

Authors:  D Allan Butterfield; Barry Halliwell
Journal:  Nat Rev Neurosci       Date:  2019-03       Impact factor: 38.755

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.